Subscription Revenue was Ernexa Therapeutics’s largest revenue line in fiscal 2020, bringing in $9.76M of $11.60M (84%).
| Products and Services | FY 2017 | FY 2018 | FY 2019 | FY 2020 |
|---|---|---|---|---|
| Subscription Revenue | $33.90M | $32.06M | $28.56M | $9.76M |
| Other Revenue | $7.11M | $7.43M | $6.36M | $984.00K |
| Hardware Revenue | $1.54M | $7.18M | $4.70M | $852.00K |
| Total | $42.55M | $46.67M | $39.61M | $11.60M |
Ernexa Therapeutics brought in $11.60M from its three revenue lines in fiscal 2020, the year ended December 31, 2020. That was down 70.7% from $39.61M in fiscal 2019. Subscription Revenue was the largest at $9.76M (84.2%), ahead of Other Revenue at $984.00K (8.5%) and Hardware Revenue at $852.00K (7.3%).
Compared with fiscal 2019, every revenue line above 2% of revenue shrank. Subscription Revenue held up best, down 65.8% to $9.76M, and Other Revenue fell the most, down 84.5% to $984.00K. From fiscal 2017 to 2020, combined revenue from these revenue lines fell from $42.55M to $11.60M, a compound annual decline of 35.2%. Subscription Revenue's share of the total rose from 79.7% to 84.2%.
United States was Ernexa Therapeutics’s largest region in fiscal 2020, bringing in $10.96M of $11.60M (94%).
| Geography | FY 2011 | FY 2012 | FY 2014 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 |
|---|---|---|---|---|---|---|---|---|
| Us | — | — | — | — | ||||
| United States | $41.14M | $45.31M | $38.31M | $10.96M | ||||
| Ca | — | — | — | — | ||||
| Canada | $1.41M | $1.36M | $1.31M | $640.00K | ||||
| Total | $42.55M | $46.67M | $39.61M | $11.60M |
Ernexa Therapeutics brought in $11.60M from its two regions in fiscal 2020, the year ended December 31, 2020. That was down 70.7% from $39.61M in fiscal 2019. United States was the largest at $10.96M (94.5%), ahead of Canada at $640.00K (5.5%).
Compared with fiscal 2019, Canada fell 51.0% to $640.00K and United States fell 71.4% to $10.96M. From fiscal 2017 to 2020, combined revenue from these regions fell from $42.55M to $11.60M, a compound annual decline of 35.2%. United States' share of the total fell from 96.7% to 94.5%.
Ernexa Therapeutics (ERNA) reports its revenue by products and services and by geography. In fiscal 2020, Subscription Revenue was its largest revenue line, bringing in $9.76M (84.2% of the total), followed by Other Revenue at $984.00K (8.5%).
Subscription Revenue was Ernexa Therapeutics' largest revenue line in fiscal 2020, bringing in $9.76M, or 84.2% of the $11.60M total across its three revenue lines.
United States was Ernexa Therapeutics' largest region in fiscal 2020, bringing in $10.96M, or 94.5% of the $11.60M total across its two regions.
Every figure comes from Ernexa Therapeutics' annual financial filings, as reported. Each line keeps the name Ernexa Therapeutics gives it, and years follow its fiscal calendar.
Ernexa Therapeutics' revenue by products and services goes back to fiscal 2017, with figures through fiscal 2020. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.